# Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

> **NCT07102901** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 351 (estimated)

## Conditions studied

- Advanced Gastric Cancer
- Metastatic Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SHR2554 Tablets
- **DRUG:** SHR-A1811 Injection
- **DRUG:** SHR-A1904 Injection
- **DRUG:** SHR-1701 Injection

## Key facts

- **NCT ID:** NCT07102901
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 351 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102901, "Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07102901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*